Literature DB >> 2201460

Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine.

B D Kahan1, L M Shaw, D Holt, J Grevel, A Johnston.   

Abstract

The optimal measurement method and clinical application of the therapeutic drug monitoring of cyclosporine remain uncertain. At a workshop held at Hawk's Cay, FL, from January 14 to January 17, 1990, 57 scientists presented their latest research findings, either in formal papers or as discussants. Lively debate and discussion followed presentation of extant and new methodologies for drug measurements as well as multicenter validation studies: applications of trough-concentration monitoring in renal, hepatic, and bone-marrow transplants as well as in autoimmune disease; and alternative pharmacokinetic approaches to guide cyclosporine therapy. The process of inducing and maintaining optimal immunosuppression to facilitate graft success is a complex and often challenging task, requiring the combined expertise of multiple disciplines. Thus, the assembly of four of the groups essential to the transplant process--clinicians, laboratory scientists, the pharmaceutical company, and the manufacturers of cyclosporine measurement kits--provided a unique opportunity to evaluate therapeutic drug monitoring issues facing the transplant field. Here we present the major conclusions reached at the meeting, brief discussions of the study data on which they are based, and a summary of unresolved problems that will require further rigorous investigations. The Consensus Document was reviewed by all the workshop participants before we submitted this final manuscript.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2201460

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  19 in total

Review 1.  Therapeutic drug monitoring of immunosuppressant drugs.

Authors:  A Johnston; D W Holt
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

Review 2.  Pharmacodynamic monitoring of cyclosporin.

Authors:  W M Awni
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 3.  Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Authors:  J Grevel
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

4.  Prediction of acute graft rejection in renal transplantation: the utility of cyclosporine blood concentrations.

Authors:  J Grevel; K L Napoli; M S Welsh; N E Atkinson; B D Kahan
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

5.  A model of prediction system for adverse cardiovascular reactions by calcineurin inhibitors among patients with renal transplants using gene-based single-nucleotide polymorphisms.

Authors:  Taisei Mushiroda; Susumu Saito; Yukiko Tanaka; Junichi Takasaki; Naoyuki Kamatani; Yoshifumi Beck; Hideaki Tahara; Yusuke Nakamura; Yozo Ohnishi
Journal:  J Hum Genet       Date:  2005-09-10       Impact factor: 3.172

Review 6.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 7.  Target concentration strategy for cyclosporin monitoring.

Authors:  R G Morris
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

8.  Feasibility of Using High-Contrast Grating as a Point-of-Care Sensor for Therapeutic Drug Monitoring of Immunosuppressants.

Authors:  Yi-Cheng Liu; Christina Thantrakul; Shu Kan; Connie Chang-Hasnain; Dong-Ru Ho
Journal:  IEEE J Transl Eng Health Med       Date:  2020-01-30       Impact factor: 3.316

9.  Cyclosporin therapeutic drug monitoring--an established service revisited.

Authors:  Raymond G Morris
Journal:  Clin Biochem Rev       Date:  2003-05

Review 10.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.